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Abstract: Andrographolide (AG) is a diterpenoid lactone isolated from the leaves of   Andrographis 
paniculata. AG is a potent and low-toxicity antileishmanial agent.   Chemotherapy applications of 
AG are, however, seriously constrained because of poor bioavailability, short plasma half-life, 
and inappropriate tissue localization. Nanoparticulation of AG was therefore envisaged as a 
possible solution. AG nanoparticles (AGnp) loaded in 50:50 poly(DL-lactide-co-glycolic acid) 
were prepared for delivery into the monocyte–macrophage cells infested with the amastigote 
form of leishmanial parasite for evaluation in the chemotherapy of leishmaniasis. Particle charac-
teristics of AGnp were optimized by proportionate application of a stabilizer, polyvinyl alcohol 
(PVA). Physicochemical characterization of AGnp by photon correlation spectroscopy exhibited 
an average particle size of 173 nm and zeta potential of -34.8 mV. Atomic force microscopy 
visualization revealed spherical nanoparticles with a smooth surface.   Antileishmanial activity 
was found to be significant for the nanoparticle preparation with 4% PVA (IC50 34 µM) in 
about one-fourth of the dosage of the pure compound AG (IC50 160 µM). AGnp therefore have 
significant potential to target the infested macrophage cells and prove valuable in chemotherapy 
of neglected tropical diseases such as leishmaniasis.
Keywords: andrographolide, nanoparticles, antileishmanial chemotherapy
Introduction
Leishmaniasis is a neglected tropical disease (NTD) caused by protozoan parasites 
belonging to the genus Leishmania. The disease is currently endemic in 88 countries 
of the developing world and showing increasing prevalence in immunosuppressive 
conditions such as HIV/AIDS.1 The World Health Organization has put out an ardent 
appeal for the development of drugs and delivery devices against leishmaniasis.2 
Therapeutic strategy today is limited to pentavalent antimony compounds such as 
meglumine antimoniate and sodium stibogluconate (SbV) with later stage applica-
tion of amphotericin B (AmB) and pentamidine. The efficacy of organic antimoni-
als is rapidly declining because drug resistance is increasing, while both AmB and 
pentamidine are associated with serious toxic side effects.3,4 Although a liposomal 
delivery device for AmB addresses some of its toxic side effects, the formulation is 
prohibitively expensive and has liposomal instability problems. Increasing lipid load 
in the treatment of systemic leishmaniasis is an added concern. Paromomycin and 
miltefosine are two very recent developments that have been intensely evaluated as 
alternative compounds in leishmaniasis chemotherapy.4,5 Development in leishmania-
sis chemotherapy is, however, far too little, mostly due to very low specificity, high 
cost, and high drug toxicity. One approach to antileishmanial chemotherapy could be International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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a systematic application of functional drug delivery devices 
carrying locally available low-cost chemotherapeutics which 
have alternative modes of action.
Andrographolide (AG), a labdane diterpenoid extracted 
from the leaves of the Indian medicinal plant Andrographis 
paniculata, is a strong antiparasitic and antileishmanial 
compound.6 Like most diterpenes, AG is sparingly soluble 
in water,7 limiting its biodistribution and localization. 
  Additionally, AG is unstable in extremes of gastrointestinal 
alkaline and acidic conditions and has a very short biological 
half-life (t½ = 2 hours).8 Development of a suitable delivery 
device for the diterpines such as AG can therefore provide 
a relatively low cost, indigenous therapeutic lead in NTDs 
such as leishmaniasis.
This work focuses on the preparation of AG nanopar-
ticles (AGnp) primarily to improve uptake in macrophage 
cells infected with the leishmanial pathogenic amastigote 
form. The Food and Drug Administration (FDA)-approved 
biopolymer for nanoparticulation, poly(DL-lactide-co-
  glycolic acid) (PLGA), has an edge for its long stabilization 
in circulation.9 Prolonged-release AG nanoparticles have 
been successfully prepared with the proportionate use of 
polyvinyl alcohol (PVA) as stabilizer and using different 
formulation variables. AGnp have macrophage-specified 
localization and have proved encouragingly efficacious in 
infective forms of leishmaniasis.
Experiment
Materials and facilities
Standard Borosil® glassware (Mumbai, India) was used for 
preparation and analysis experiments. A Vibra cell VCX 750 
700 MW sonicator (Sonics, Newtown, CT), a homozinizer 
model TH 02 (Omni International, Kennesaw, GA), 
a   Mettler-Toledo AL54 0.00001-g precision balance (Mettler, 
Columbus, OH), a Tarsons Accupipet (Tarsons, Calcutta, 
India), and a Himac CS120GHXL ultracentrifuge (Hitachi 
Koki, Tokyo, Japan) were used in preparative processes. 
Chemical analyses were carried out in a Waters dual pump 
HPLC model 515 (Waters, New Castle, DE). A zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK), a Nanoscope 
3A atomic force microscope (Veeco, Plainview, NY), a 
FT-IR 670 Plus (Jasco, Tokyo, Japan), and a fluorescence 
microscope (BX51, Olympus, Center Valley, PA) were used 
for most particle characterization and imaging experiments. 
All solvents used were of HPLC grade and of E. Merck or 
Spectrochem brand. Water used was of millipore grade, 
Elix 3 Century ZLXS5003Y (Millipore, Billerica, MA). 
PLGA (50:50, MW 40,000–75,000), dialysis tubing D9652 
(MW cut off 12,400), FITC (fluorescein 5(6)-isothiocyanate), 
PVA (89,000–98,000), and RPMI-1640 cell culture medium 
were purchased from Sigma-Aldrich (St. Louis, MO). 
Andrographolide was purchased from Natural Remedies 
(Bangalore, India) while SbV was a generous gift from 
Albert David Ltd. (Kolkata, India) and AmB was purchased 
from Sigma-Aldrich. Windows Excel 2003 version and 
Sigmaplot 6.0 (Zendal Scientific, USA) were used for the 
data analysis.
Methods
Preparation of Agnp
AG nanoparticles were prepared following an emulsion 
solvent evaporation technique. A combination of both 
sonication and homogenization was used to increase shear 
stress during emulsification to produce small size particles 
with higher drug loading. Briefly, 50 mg PLGA and 2.5 mg 
of AG were dissolved together in 3 mL of chloroform. 
This phase was emulsified by sonication for 1 minute in 
12 mL of different concentrations w/v (2% Formulation 
A, 4% Formulation B, and 6% Formulation C) of aque-
ous PVA at 20 kHZ. The resultant oil/water emulsion was 
homogenized for 20 minutes at 20,000 rpm under external 
cooling in ice water. The solvent evaporation was continued 
for 12 hours over a magnetic stirrer at room temperature. 
The nanoparticles (AGnp) formed were harvested by ultra-
centrifugation at 30,000 rpm for 25 minutes at 4°C. AGnp 
were washed with water, recentrifuged, and preserved in 
vacuum desiccators at 4°C until further evaluation. Each 
formulation was prepared in quadruplicate for analysis in 
later stages (Table 1).
Fluorescent PLGA nanoparticles (FAGnp) were prepared 
in a similar fashion where FITC was used in place of AG.
Particle size and polydispersity
The particle size of AGnp preparations was measured in a 
zetasizer Nano ZS against a 4 mw He–Ne laser beam, 633 nm, 
and back scattering angle of 173°. Aliquots from each prepa-
ration batch were sampled in cuvettes and particle size along 
with polydispersity index (PDI) were determined.
Zeta potential
Zeta potential of the AGnp preparations was measured in 
a zetasizer set up. Aliquots from preparation batches were 
sampled in disposable zeta cells and zeta potentials were 
determined on the basis of electrophoretic mobility under 
an applied electrical field.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Atomic force microscopy
AGnp suspensions (100 µL) in water were deposited onto 
fused mica substrates. The particles were visualized in atomic 
force microscopy (AFM) in tapping mode using an RTESP 
tip with 267 to 328 kHz resonance frequency at a scan speed 
of 1.2 Hz.
Fourier transform infrared (FTIR) studies
FTIR studies were carried out to observe any AG and bio-
polymer interactions. AG, a blend of AG with PLGA, and 
PVA and a blend of PLGA and PVA were diluted separately 
with IR grade KBr in the ratio 1:100 and were pelletized 
(1000 psi). The pellets were scanned over a wave number 
range of 4000 to 400 cm-1 and the data stacked in Bio-Rad 
KnowItAll (Bio-Rad, Hercules, CA) software to compare 
and search for any chemical interactions.
AG entrapment efficiency (%)
All AG estimations were carried out in a reverse phase 
HPLC system. The mobile phase was acetonitrile: 0.1% 
(v/v) phosphoric acid in water (40:60, v/v) at a flow rate 
of 1 mL/min. The analysis was carried out using a C18 
column (Supelco, Bellefonte, PA), 25 × 4.6 mm, and a PDA 
detector (2996, Waters). A peak area (y) vs concentration 
(x) graph for AG was first prepared, y = 28051x + 51747, 
R2 = 0.9979; retention time was 4.5 minutes. This was used 
to detect AG concentrations throughout. Mass of AG in 
solution before and after nanoparticulation in supernatant 
was determined in HPLC experiments for calculation of 
entrapment efficiencies.10
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In vitro release studies
AGnp equivalent to about 2 mg of AG load were dispersed 
in 1 mL of phosphate buffer (100 mM, pH 7.4) and the 
dispersion was carefully washed into a dialysis bag. The 
dialysis bags were placed in glass vials containing 10 mL of 
phosphate buffer and maintained at 37°C in a shaker bath. 
At predetermined time intervals, the release medium in 
vials was taken out and replaced with fresh buffer medium. 
The amount of AG released per timed sample was estimated 
in HPLC. A standard curve plot was used for analysis with 
necessary corrections for the dilution factors. The in vitro 
release and kinetics for all three types of preparations were 
similarly studied. In order to understand the molecular 
release mechanism, the Korsemeyer–Peppas model was 
applied and n and K values were calculated using Sigmaplot 
6.0 software.
Nanoparticle uptake  
by fluorescence microscopy
In order to study nanoparticle uptake, macrophages (4 × 105 
cells/well) were seeded with FAGnp (0.5 mg/mL), incubated 
for 2 to 4 hours, and observed in FITC channel under a 
  fluorescence microscope.
Assessment of antileishmanial activity
Parasites and macrophages
Leishmania donovani AG 83(MHOM/IN/1983/AG83)11,12 
was isolated from an Indian patient with kala-azar. 
  Macrophages were collected by peritoneal lavage from mice 
(Swiss albino, female 22 ± 2 g) given with intraperitoneal 
injection of 0.5 mL (4%) of thioglycolate broth 5 days before 
harvest. Cells were grown on RPMI-1640 medium supple-
mented with 2 g/L NaHCO3, 10% fetal calf serum, 100 U 
penicillin, and 50 µg streptomycin/mL. Exudate cells were 
harvested from the peritoneal cavity in RPMI-1640 medium 
and plated onto tissue-culture dishes with 35 mm diameter 
wells. After incubation for 2 hours at 37°C, nonadherent 
cells were removed by thorough washing. The remaining 
adherent macrophages were cultured for 24 hours at 37°C 
in an incubator (5% CO2/air) for further studies. Cultures 
prepared in this manner contained $95% macrophages, 
as evaluated by their ability to take up latex beads and by 
morphology.
Table 1 characterization of Agnp preparations
AGnp  
preparations
Particle  
size (nm)
Zeta potential  
(mV)
PDI Entrapment   
efficiency %
Formulation A 426 ± 21.2* -22.2 ± 2.1 0.155 ± 0.03 59 ± 4.4**
Formulation B 173 ± 12.6*  -34.8 ± 1.4 0.229 ± 0.01 80 ± 3.5*
Formulation c 225 ± 18.4 -34.2 ± 1.8 0.468 ± 0.02 56 ± 5.2
Notes: Results expressed as mean ± sD (n = 4); *P , 0.01 significant difference compared with Formulation C; **P , 0.5 no significant difference compared with Formulation C.
Abbreviations: Agnp, andrographolide nanoparticles; PDI, polydispersity index.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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L. donovani amastigotes were grown and maintained as 
described by Debrabant et al.13 Axenically grown amastigotes 
were maintained at 37°C with 5% CO2/air by weekly subpas-
sages in MAA/20 (medium for axenically grown amastigotes) 
at pH 5.5 in 177 cm2 petri dishes.14 Under these conditions, 
promastigotes differentiated to amastigotes within 120 hours. 
Cultures were maintained by 1:3 dilutions once a week.
Axenic amastigote Ag susceptibility assay
Susceptibility determinations of L. donovani axenic amastig-
otes were carried out using a modification of the promastigote 
direct counting growth inhibition assay.15 Amastigotes were 
seeded at an initial concentration equivalent to early log 
phage (3 × 105 amastigotes/mL) and allowed to   multiply 
for 72 hours either in medium alone or in presence of 
serial   dilutions of drug or inhibitor until late log phage 
(1 × 106 cells/mL). Axenic amastigote numbers doubled 
3 to 4 times during the assay. AG susceptibility experiments 
were performed in the maintenance media. The 50% inhibi-
tory concentration (IC50) for the test drug was determined. 
Amastigotes were counted microscopically using a hemo-
cytometer after being passed 3 times through a 27-gauge 
needle in order to separate any clumps, as part of a standard 
procedure and cell determination accuracy. All experiments 
were done in triplicate.
Amastigote in macrophage  
Ag susceptibility assay
AG susceptibility of L. donovani was determined by following 
a modification of the method of Chang.16 Briefly,   macrophages 
were seeded at 4 × 104 cells/well in α-10 medium with 
chamber slides. Following a day treatment at 37°C to allow 
attachment, macrophages were infected with axenic amas-
tigotes (4 × 105 amastigotes/well) in α-10 medium and then 
incubated for 4 hours at 37°C to allow infection. The chamber 
slides were washed once with Dulbecco’s phosphate-buffered 
saline. AG solutions diluted in α-10 medium were added to the 
appropriate wells and the slides were incubated at 37°C for a 
further 72 hours before staining with Giemsa. Medium and 
AG solutions were replaced with fresh ones every 24 hours. 
The initial infection was determined by fixing 2 wells with 
Giemsa immediately following a 4-hour incubation. Control 
wells of infected macrophages were incubated in medium 
alone to determine the doubling times of amastigotes in 
macrophages over the experimental duration (72 hours). The 
viabilities of AG treated or untreated macrophages were also 
assessed at 72 hours. Experiments were done in triplicate. The 
initial percentage of macrophages infected with amastigotes 
was determined by microscopic inspection (100×) of the cells. 
IC50 of the test solutions was determined based on the value 
of number of amastigote per macrophage.
cytotoxicity against mammalian 
macrophages
Macrophages cells were cultured in minimum essential 
medium (MEM, Gibco), supplemented with 20 mM 
L-glutamate, 16 mM NaHCO3, 5% fecal calf serum and 
penicillin–streptomycin. The assay was performed in 96-well 
tissue culture plates in the presence of standard counts of 
macrophages. The wells were seeded with test solutions and 
the viable macrophages were counted microscopically.
statistical analysis
Experimental results were expressed as mean ± standard 
deviation. Student’s t-test was used to calculate the statisti-
cal difference of mean values. Differences were considered 
significant at P , 0.01.
Results
Limited solubility of AG was a major constraint in the prefor-
multion stages. Ethanolic solution of AG caused precipitation 
of the biopolymer in the emulsification stage. AG dissolved 
in DMSO and ethyl acetate failed to load, because of higher 
loss of diffusive mass. Chloroform was used as a solvent as it 
can keep both AG and PLGA together in solution and enable 
optimization experiments in particle size and loading.17 Three 
categories of AGnp were prepared varying in stabilizer PVA 
concentration (Table 1). Nanoparticles prepared in the sonica-
tion and homogenization procedure were evenly distributed 
and relatively small. In other experiments, initially when 
only a homogenization step was used for dispersion, larger 
particle size, irregular drug load, and skewed particle distri-
bution were observed.18 PLGA nanoparticle preparations in 
a sequential application of sonication and homogenization 
provided better control of particle sizing and drug loading. 
A clear stable dispersion of AGnp in water with a color tint 
due to AG loading was obtained (Figure 1).
Nanoparticle size and zeta potential
The particle size, PDI, and zeta potential for all AGnp prepa-
rations were studied in PCS and the results are presented in 
Table 1. PVA stabilizer appeared to have a distinct role both 
in nanoparticle size and PDI. Formulation A, having low PVA 
concentration of 2%, produced larger size particles of 426 nm 
and a much reduced PDI of 0.155. In Formulation B, particle 
size was around 173 nm, when 4% w/v of PVA was used. International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Increasing the concentration of PVA had an oscillating effect, 
and in Formulation C where 6% w/v PVA was used, particles 
were 225.3 nm and PDI was 0.468 with little skewness in 
particle distribution. Formulation B had a zeta potential of 
-34.8 mV with a near perfect Gaussian particle distribution. 
The observations were consistent with earlier findings.18
AFM surface topography
AFM was extensively used to understand the particle surface 
topography for AGnp. The 3D amplitude data of every AGnp 
preparation exhibited a spherical shape with a smooth solid 
surface and minimal coalescence. Figure 2 shows an AFM 
study of an observation zone and 3D surface characteristics 
of individual particles from Formulation B.
FTIR studies for exipient interactions
Because AG is a delicate phytoconstituent, prior study 
was important to determine if there was any type of 
chemical interaction with the biopolymer materials used in 
nanoparticulation.
FTIR scan for AG was typical and the AG O–H stretch-
ing vibrations appeared at 3402 cm-1, indicative of an inter-
molecularly hydrogen bonded structure. C–O stretching 
appeared at 1030 cm-1 and at 1078 cm-1 for the primary and 
the secondary alcoholic functions. Corresponding in plane 
O–H bending responded at 1420 cm-1 and the characteristic 
AG lactone responded at 1727 cm-1 (Figure 3).19 PLGA and 
PVA biopolymers individually and when blended together 
responded at 2935 cm-1 due to linear CH2 stretching and at 
1756 cm-1 due to the ester bond, respectively. The biopoly-
mer blend did not show any absorbance in specific regions 
of AG reactive functional groups.20 When AG was blended 
with PLGA and PVA and scanned in FTIR, all AG functional 
groups remained intact in position, showing that there was 
no appreciable chemical interaction between AG and the 
biopolymer materials used.
Nanoparticle drug entrapment
Effectiveness of a drug delivery device is directly dependent 
on its drug payload. Payload efficiency, often termed entrap-
ment efficiency, is an important determinant for preparation 
process efficiencies. AG entrapment in PLGA was observed 
in quadruplicate for all formulations (Table 1). Formulation 
B showed the highest entrapment efficiency of 80 ± 3.5%.
In vitro drug release and release kinetics
The time-dependent in vitro release of AG was studied, 
and the average percentage cumulative release over time is 
  plotted in Figure 4. The release responses for all formula-
tions were biphasic in nature. The initial release (burst effect) 
was fast, indicative of some nanoparticle surface-adsorbed 
AG   molecules. The release, however, remained fast for 
a   prolonged period of 720 hours.
The faster release rate was recorded in the initial 48 hours 
followed by a sustained release period for the remaining AG 
payload. In Formulation A, however, almost 65% of payload 
was released in media in 48 hours, indicating that the concen-
tration of PVA used is important not only for PLGA particle 
sizing but also to enable drug entrapment.18 Formulation B 
therefore appeared most promising because of its superior 
drug load, appropriate Gaussian particle distribution, and 
sustained release over a sufficiently prolonged period.
The order kinetics for all preparations was statistically 
evaluated. AG in vitro release for Formulation B was observed 
following zero order kinetics, consistent with prolonged-release 
particulate drug delivery devices. Understanding the payload 
release mechanism for particulate delivery systems is an impor-
tant criterion for further correlations. The   Korsemeyer–Peppas 
model (equation 1) describes the release mechanism of particu-
late delivery devices over a time range.21
  Mt/Mα = Ktn  (1)
Figure  1  Andrographolide  (Ag)  and  andrographolide  nanoparticles  (Agnp)  in 
water medium. A) AG flakes insoluble in water. B) Agnp (Formulation B) colloid 
in water.
B A
100
200
300
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Figure  2  Atomic  force  microscopy  study  of  andrographolide  nanoparticles. 
A)  single  particle  3D  surface  topography.  B)  2D  study  of  particle  distribution 
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Where, Mt, mass released at time point ‘t’, Mα, total mass 
load, n is the release exponent, and K is the constant accom-
modating the structural and geometric features.
AG mass release for Formulation B nanoparticles pro-
vided a good fit (Table 2). The n value recorded was 0.33, 
indicating the release mechanism is not a simple Fickian 
diffusion22 for AGnp. This could appear when mass release 
is associated with slow polymer surface erosion or a bulk 
mass penetration. AFM studies were carried out separately 
on particles sampled from after 360 hours of exposure 
in release media. Nanoparticles sampled after 600 hours 
of release evidenced distinct erosion on PLGA polymer 
surfaces (Figure 5). This clearly explained surface erosion 
associated with in vitro release mechanism in later hours of 
AG release.
In vitro antileishmanial  
activity and cytotoxicity
The susceptibilities of both the axenic and intracellular amas-
tigotes to AG and 3 AGnp preparations were evaluated fol-
lowing standard protocols. The IC50 values in each case were 
compared against a known antileishmanial compound, SbV. 
AG itself was a superior antileishmanial to SbV both in 
axenic amastigote and in vitro macrophage infective forms. 
Additionally, cytotoxicity due to AG was at least half that of 
SbV (Table 3). AGnp in Formulation B was, however, almost 
5 times as efficacious as AG and about 8 times that of SbV 
in macrophage infective forms of amastigotes. Superior 
efficacies of AGnp were primarily attributed due to their 
improved localization in macrophage cells. Additionally, 
the small negative surface charge on nanoparticles pre-
pared provided a colloidal dispersion that was conducive to 
entrapment onto nonflagellated amastigotes. A clear order 
in potency can therefore be shown as Formulation B . For-
mulation A . Formulation C . AG . SbV. AmB, a strong 
antileishmanial antibiotic, was also evaluated. Leishmanicidal 
activity of AmB was profound and was similar in axenic 
amastigote and microphage infested amastigotes, (IC50 
0.2 ± 0.1 µM and 0.15 ± 0.1 µM, respectively). AmB was, 
however, exceedingly cytotoxic, 50% cytotoxicity concen-
tration (CC50) .13 µmole, while CC50 due to AG was .103 
µmole and that of Formulation B was .2 × 103 µmole. 
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Figure 3 A) Fourier transform infrared overlay of entire region. B) Overlay at cOh region. C) Overlay at cOh region and ch2 region.
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A separate set of experiments with FITC-loaded nanoparticles 
prepared similarly showed a considerable macrophage uptake, 
peaking within 2 hours of incubation as observed under 
fluorescence microscopy (Figure 6). Empty nanoparticles 
without any AG load, when tested both for cytotoxicity and 
antileishmanial activity, have proved sufficiently innocuous 
even up to the tested dosage of 110 µg/µL. AGnp antileish-
manial activity was attributed to the AG payload and to 
macrophage localization.
Discussion
Chemotherapy is the principal option in treatment of 
leishmaniasis.23 The parasitic disease is presently showing 
increasing prevalence due to multiple factors, including 
resistance to traditional chemotherapeutic agents,   difficulties 
in drug localization, worsening immune environment in 
  developing countries, and population migration and preva-
lence of other infective immune diseases such as HIV/AIDS. 
Prohibitive cost and the time lag in development of new 
  chemotherapeutics are other hurdles.
Plant-derived antileishmanials with minimal inherent 
toxicities are emerging alternatives in chemotherapy of 
leishmaniasis.24–26
The antileishmanial compound AG could provide an 
excellent low-cost alternative if its problems of solubilization and 
localization could be solved. AG, an indigenous phytomedicine, 
can be readily purified from a plant source, A. paniculata.27 
In addition AG combines immunomodulation and anti-HIV 
potentials acting via viral tyrosine kinase inhibition.27
Solubility characteristics of the test drug and the 
biopolymer, however, often dictate the choice of nano-
particle preparation technique. Both AG and PLGA were 
  proportionately soluble in chloroform. The role of a stabilizer 
was observed to be crucial for particle size and success of 
later cellular uptake for both AG and PLGA. Proportionate 
application of the stabilizer PVA provided smooth spherical 
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Figure 4 In vitro release profile of andrographolide nanoparticle preparations. Results expressed as mean ± sD (n = 3).
Table 2 Korsemeyer–Peppas release kinetics modeling for Agnp
AGnp 
preparation
Korsemeyer–Peppas 
model parameters
Formulation A n = 0.26 K = 0.19
Formulation B n = 0.33 K = 0.09
Formulation c n = 0.29 K = 0.09
Abbreviation: Agnp, andrographolide nanoparticles.
Figure 5 Atomic force microscopy of andrographolide (Ag) nanoparticles before 
and after dissolution. A) Formulation B before release. B) Formulation B, 600 hours 
after Ag release.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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  nanoparticles having narrower Gaussian size distribution 
(Table 1).   Formulation B nanoparticles showed a negative 
zeta potential of -34.8 mV, therefore providing prolonged 
stabilization in suspension, which is required for cellular 
internalization. Higher drug loading efficiency of up to 
80% w/w can be attributed to optimized particulation and 
entrapment or for polymer and drug chemical interactions. 
The chemical interactions of AG with the polymer and the 
stabilizer components were therefore checked in FTIR and no 
major chemical interaction was observed. AG mass appears 
ideally localized in particular PLGA nanoparticles. The drug 
release mechanism for the new AG–PLGA nanoparticles was 
observed following a diffusion and surface erosion mecha-
nism. This was explained in later AFM studies (Figure 5) 
showing extensive polymer erosion and drug diffusion. 
Antileishmanial efficacy of AG was significantly improved 
in AGnp due to particle characteristics and successful local-
ization of AGnp in infested macrophages, as evidenced by 
fluorescent nanoparticle internalization (Figure 6). AG loaded 
in PLGA nanoparticles therefore has reasonable potential 
for further application in chemotherapy of leishmaniasis. 
Molecularly, the diterpenoid AG28 reacts with active cysteine 
residues, effectively inducing extrusion of cellular glutathi-
one and converting the intracellular oxy radicals to H2O2. 
AG triggers an alternation of intracellular reactive oxygen 
species and eventually induces collapse of mitochondrial 
membrane potential. AG was also shown to effectively inhibit 
mitotic cell division and G2/M arrest in highly proliferating 
cancerous cells. Earlier work has established some limited 
successes with liposomal delivery of AG.6 Additionally, 
attempts to deliver an active AG metabolite, 14-deoxy-11
-oxo-andrographolide, using different drug carriers have 
established an inverse linear relationship between the size 
of the carriers and antileishmanial efficacy.29 A major con-
straint in antileishmanial chemotherapy is the development 
of drug resistance implicitly linked to cellular transporters.23 
Nanoparticle cellular uptake is markedly dependent on size 
and surface charge.30 Nanoparticles in a size range below 
200 nm are associated with increased phagocytosis and can 
easily localize in macrophages predominantly infested with 
leishmanial parasite.31 The phagolysosomal pH is acidic 
around pH 4.5 to 5.0 and the acidic environment has impli-
cations in the infested amastigote strategies for faster nutri-
ent acquisition and ion homeostasis.4 PLGA, on the other 
hand, degrades relatively easily at acidic pH32 and the acidic 
monomers formed further autocatalyze the biodegradation. 
Size-defined AG nanoparticles in PLGA can therefore boost 
antileishmanial chemotherapy.
Conclusions
Limiting parameters for indigenous low-toxicity plant-
derived chemotherapeutics in leishmaniasis can thus be 
overcome by nanoparticulation in PLGA followed by drug 
localization in infected cells of the reticuloendothelial 
  system. Compounds such as AG nanoparticles may provide 
effective low-cost chemotherapy of leishmaniasis acting 
through an alternative mechanism.
Table 3 Antileishmanial activity of Ag, Agnp, and standard antileishmanial agents against L. donovani
Activity (IC50 ± SD or CC50) in μM concentrations 
Drug tested Axenic amastigote  
(IC50 ± SD)
Amastigote in macrophage 
(IC50 ± SD)
Cytotoxicity assay 
(CC50)
Formulation A   64 ± 8* 54 ± 5* .1.2 × 103
Formulation B   36 ± 4* 28 ± 2* .2 × 103
Formulation c   76 ± 6* 62 ± 8* .1.8 × 103
Andrographolide 160 ± 26 141 ± 21 .103
stibogluconate 410 ± 60* 246 ± 37** .2.4 × 103
Amphotericin B  0.2 ± 0.1* 0.15 ± 0.1* .13
Notes: Results expressed as mean ± sD (n = 3); *P , 0.01 significant difference compared with AG; **P , 0.05 no significant difference compared with AG.
Abbreviations: Ag, andrographolide; Agnp, andrographolide nanoparticles; Ic50, inhibitory concentration 50%; CC50, cytotoxicity concentration 50%.
Figure  6  Andrographolide  nanoparticles  in  macrophages  under  fluorescence 
microscope after 2 hours’ incubation.International Journal of Nanomedicine
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